FAQ: Gyre Therapeutics' Progress on Hydronidone Approval and Clinical Pipeline Expansion
Summary
Gyre Therapeutics has advanced toward China approval for Hydronidone to treat liver fibrosis, supported by positive Phase 3 data, and expanded its clinical pipeline with new drug developments. This progress positions the company for potential commercial launch in FY2027 and strengthens its role in addressing chronic liver diseases.
What is the main focus of Gyre Therapeutics as described in the content?
Gyre Therapeutics is a biopharmaceutical company primarily focused on developing and commercializing Hydronidone for liver fibrosis, including MASH (metabolic dysfunction-associated steatohepatitis), in the United States, while also advancing a broader pipeline in China through Gyre Pharmaceuticals.
What progress has Gyre made with Hydronidone in China?
Gyre has submitted an application for Hydronidone approval in China, supported by Phase 3 data that met the primary endpoint of fibrosis regression in chronic hepatitis B-associated fibrosis. With Breakthrough Therapy Designation, approval is anticipated in the second half of 2026.
When is the commercial launch of Hydronidone expected in China?
The commercial launch of Hydronidone in China is expected in FY2027, following anticipated approval in the second half of 2026.
What clinical trials are ongoing for Hydronidone in the U.S.?
Gyre has initiated a U.S. Phase 2 trial for Hydronidone, as part of its development strategy for liver fibrosis, building on mechanistic studies and previous clinical research.
Who is the new CEO of Gyre Therapeutics?
Dr. Han Ying, who has been a board member since January 2025, was named as the CEO of Gyre Therapeutics.
What other products or pipelines is Gyre advancing in China?
In China, Gyre is advancing a broad pipeline through Gyre Pharmaceuticals, including therapeutic expansions of ETUAR(R), and development programs for F573, F528, and F230.
Where can I find more information about Gyre Therapeutics?
For more information, visit Gyre Therapeutics’ website at https://www.gyretx.com/ or view the full report at https://ibn.fm/9wCTA.
Why is the progress with Hydronidone significant?
The progress is significant because Hydronidone has shown efficacy in fibrosis regression in Phase 3 trials, potentially offering a new treatment for chronic liver diseases like hepatitis B-associated fibrosis and MASH, with Breakthrough Therapy Designation speeding up its approval process.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 202386